HC Wainwright Has Positive Forecast for DBVT FY2024 Earnings

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for DBV Technologies in a research note issued to investors on Wednesday, October 23rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($1.41) for the year, up from their prior estimate of ($1.43). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for DBV Technologies' FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

DBVT has been the subject of several other reports. StockNews.com began coverage on DBV Technologies in a research note on Monday. They issued a "hold" rating for the company. JMP Securities reiterated a "market outperform" rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Up 3.5 %

DBVT stock traded up $0.03 during trading on Friday, hitting $0.87. The company had a trading volume of 1,245,455 shares, compared to its average volume of 235,903. The firm has a 50-day moving average price of $0.77 and a 200-day moving average price of $0.96. DBV Technologies has a 12 month low of $0.50 and a 12 month high of $2.28. The stock has a market cap of $83.61 million, a price-to-earnings ratio of -1.03 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.42 million. During the same period in the prior year, the firm posted ($0.26) earnings per share.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,568,909 shares of the company's stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.'s investment portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities and Exchange Commission. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.